RGCC Oncocount is a follow-up tool for cancer patients undergoing treatment, offering insight into the effectiveness of therapies and monitoring disease progression. Circulating Tumor Cells (CTCs) serve as potent biomarkers, their presence in the bloodstream signaling a potential resurgence of cancer.
The RGCC Oncocount test serves as a monitoring tool utilized during and post-treatment to assess the effectiveness of your cancer therapy and facilitate early detection of recurrence or relapse. Enumerating circulating tumor cells (CTCs) acts as a prognostic factor, assisting clinicians in anticipating the disease progression and executing appropriate treatment approaches.
CTCs presence: Can be used as a predictive biomarker to set the stage for further analysis, including molecular profiling, immunophenotyping, gene expression assays, and sensitivity assessments of various treatment modalities.
CTC Concentration: Is often correlated as a prognostic indicator, Higher CTC counts are associated with poorer prognosis and increased risk of disease progression and recurrence.
A significant decrease in CTC numbers following treatment may indicate a positive response to therapy. If the decrease in CTC count is low, it may indicate the necessity for adjustments in treatment protocols or even incorporating supplementary therapies.
Oncocount used as a follow-up test offers insight into the effectiveness of cancer therapy and facilitates early detection of recurrence or relapse of several cancers.
The test applies to all types of cancers except the one in the central nervous system and is not just limited to the following.
The first step towards personalized cancer care is scheduling an appointment with us.
Upon booking the appointment, you get a consultation with our RGCC experts to assess your cancer status.
We guide you through the process of selecting the most effective tests for your specific cancer.
We deliver precise results that guide treatment decisions and enhance outcomes.
“RGCC’s Oncocount test is crucial for monitoring cancer recurrence and guiding long-term treatment strategies. Its precision enables proactive management, improving patient outcomes and quality of life. A vital component of comprehensive cancer care.”
Our RGCC accredited experts are here to help you with their expertise and guide you in your fight against cancer.
A simple non-invasive test to monitor cancer.
We suggest undergoing followup tests every three months during active cancer treatment to evaluate the efficacy of the ongoing treatment plan.
Every 3 months for 1 year after completing the treatment to monitor for early relapse/recurrence. Once patients achieve full remission, the test is recommended every six months.
Our cutting edge diagnostics and personalised tests makes a meaningful difference in the fight against cancer.
Absolutely, tests can be performed while undergoing treatment to assess the effectiveness of the treatment against cancer.
Your blood sample undergoes processing in cutting-edge laboratories by scientists and technicians to deliver insights into your cancer cells.
Yes, all RGCC tests utilize blood samples. However, certain cancers, like glioblastoma and brain tumors, may require additional samples such as CSF or tissue. Otherwise, a peripheral blood sample alone is enough.
Yes, tests like aCGH can pinpoint the origin of an unknown primary tumor by analyzing genetic abnormalities present in tumor cells.
RGCC Metastat is an effective test for identifying secondary tumors development and its potential location. It helps detect secondary tumors through analyzing Circulating Tumor Cells (CTCs) in the bloodstream. The test provides valuable insights into disease progression and metastasis.
Tests personalize treatment regimens by providing crucial information on drugs and therapies tailored to effectively target cancer cells.
Circulating Tumor Cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream. Cancer Stem Cells (CSCs) are a subpopulation of CTCs and both serve as biomarkers for cancer.
Tests like ChemoSNiP and CAMBISeq provide information on the body’s response to the drugs and sensitivity to immunotherapy.
Detect the potential recurrence of cancer early with precise monitoring of Circulating Tumor Cells (CTCs), you can take control of your cancer journey. RGCC Oncocount empowers clinicians and patients with proactive monitoring to stay ahead in your fight against cancer.
Offering personalized tests from RGCC, our mission is to improve treatment outcomes, enhance survival rates, and elevate overall quality of life for those affected by cancer.
Copyright 2024 © All Right Reserved.
Designed by Bee High Media